PTC
KROS icon

Private Trust Company’s Keros Therapeutics KROS Stock Holding History

Private Trust Company’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-81
Closed -$825 – 2531
2025
Q1 		$825 Hold
81
– – ﹤0.01% 2384
2024
Q4 		$1.28K Buy
+81
New +$4.21K ﹤0.01% 2220

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Private Trust Company's KROS Position: Q2 2025 in Review

Private Trust Company sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 81 shares — an estimated $825 sold.

Private Trust Company first reported a position in KROS in Q4 2024 and held it in 2 quarters. The position peaked at $1.28K in Q4 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Private Trust Company reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Private Trust Company sold 81 Keros Therapeutics shares in Q2 2025, an estimated $825.
  • Private Trust Company first reported a position in Keros Therapeutics in Q4 2024 and held it in 2 quarters.
  • Private Trust Company's Keros Therapeutics position peaked at $1.28K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Private Trust Company's 13F filing for Q2 2025, filed 29 Jul 2025.